INVA Key Statistics, Chart & Performance
The current stock price of INVA is 19.65 USD. In the past month the price decreased by -5.12%. In the past year, price increased by 13.72%.
INVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.35 | 1.03T | ||
| JNJ | JOHNSON & JOHNSON | 19.82 | 495.71B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.48B | ||
| PFE | PFIZER INC | 7.9 | 143.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.80B | ||
| ZTS | ZOETIS INC | 20.01 | 55.90B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.8 | 23.24B | ||
| VTRS | VIATRIS INC | 5.41 | 14.51B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.21 | 11.55B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.72B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About INVA
Company Profile
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Company Info
INNOVIVA INC
1350 Old Bayshore Highway, Suite 400
Burlingame CALIFORNIA 94010 US
CEO: Pavel Raifeld
Employees: 127
Phone: 16502389600
INNOVIVA INC / INVA FAQ
Can you describe the business of INNOVIVA INC?
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Can you provide the latest stock price for INNOVIVA INC?
The current stock price of INVA is 19.65 USD. The price increased by 0.56% in the last trading session.
Does INVA stock pay dividends?
INVA does not pay a dividend.
What is the ChartMill rating of INNOVIVA INC stock?
INVA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of INNOVIVA INC (INVA)?
The PE ratio for INNOVIVA INC (INVA) is 14.34. This is based on the reported non-GAAP earnings per share of 1.37 and the current share price of 19.65 USD.
Can you provide the upcoming earnings date for INNOVIVA INC?
INNOVIVA INC (INVA) will report earnings on 2026-02-24, after the market close.
What is the outstanding short interest for INNOVIVA INC?
The outstanding short interest for INNOVIVA INC (INVA) is 7.33% of its float.
INVA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to INVA. When comparing the yearly performance of all stocks, INVA is one of the better performing stocks in the market, outperforming 70.67% of all stocks.
INVA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INVA. INVA gets an excellent profitability rating and is at the same time showing great financial health properties.
INVA Financial Highlights
Over the last trailing twelve months INVA reported a non-GAAP Earnings per Share(EPS) of 1.37. The EPS increased by 98.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.78% | ||
| ROA | 8.91% | ||
| ROE | 12.61% | ||
| Debt/Equity | 0.25 |
INVA Forecast & Estimates
10 analysts have analysed INVA and the average price target is 33.15 USD. This implies a price increase of 68.7% is expected in the next year compared to the current price of 19.65.
For the next year, analysts expect an EPS growth of 1027.37% and a revenue growth 12.59% for INVA